RFA-RM-26-002
NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)
Summary
NIH Director's New Innovator Award
This program funds early-stage investigators pursuing exceptionally creative, bold research with potential for major impact across biomedical sciences. The award targets researchers proposing high-risk, high-reward projects that challenge conventional approaches—spanning systems biology, disease mechanisms, therapeutic development, and computational biology. Successful applications typically present innovative methodologies or translational research that could reshape understanding of fundamental biological processes or accelerate therapeutic discovery. The program welcomes applications across all biomedical disciplines and is part of the NIH Common Fund's broader High-Risk, High-Reward Research initiative.
- Who can apply: Early-stage investigators of exceptional creativity; applications in any biomedical science area welcome.
- Funding & project length: Not stated.
- Award mechanism: DP2 (Director's New Innovator Award).
- Key dates: Not stated.
- Best fit for: Early-career researchers in biomedical sciences (computational biology, systems biology, translational research) proposing unconventional, high-impact projects.
Insights (5)
ESI-exclusive mechanism with significant portfolio-building value for early investigators
The New Innovator Award is explicitly restricted to early-stage investigators (ESI), making it a rare opportunity to compete in a dedicated, less-crowded pool. Success here provides both substantial funding ($1.5M over 5 years, typical for DP2s) and a prestigious Common Fund award that signals exceptional creativity—valuable for establishing independence and securing future R01 funding.
High-risk, high-reward framing demands genuinely novel approaches, not incremental advances
The program explicitly seeks 'bold and highly innovative research' within the HRHR framework, meaning reviewers expect transformative potential and methodological novelty, not refinement of established paradigms. Applicants should emphasize preliminary data demonstrating feasibility of a risky idea, not a safe, incremental project with strong preliminary results.
Broad scope and Common Fund prestige likely drive high competition despite ESI restriction
Because applications in 'any area within the biomedical sciences' are welcome and the award carries significant prestige, competition is expected to be intense even within the ESI pool. The mechanism funds only ~50 awards annually across all NIH, making this highly selective despite the ESI advantage.
Systems biology and computational approaches align with program's innovation emphasis
The enrichment keywords (systems biology, computational biology, innovative methodologies) suggest reviewers value integrative, cross-disciplinary approaches that challenge conventional thinking. Applicants with computational or systems-level framing of disease mechanisms or therapeutic development will likely be more competitive than those proposing traditional bench approaches.
ESI definition is strict; verify your institution's interpretation of 'independent research position'
ESI status requires holding an independent research position (typically R01-equivalent) for ≤10 years since terminal degree. Postdocs, clinical fellows, and researchers in non-independent roles are ineligible. Confirm your institution's grants office has verified your ESI status before investing effort, as borderline cases (e.g., recent transition to independence) may be challenged.
Key Facts
Deadline
—
Posted
Thu, December 11, 2025
Award Range
$475,000 – $475,000
Expected Awards
30
Keywords
Research Areas